DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapyECCO'19 Copenhagen
2019
1
DOP62: A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-label Randomised Controlled Trial in Patients with Active Crohn’s DiseaseECCO'19 Copenhagen
2019
1
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort studyECCO'19 Copenhagen
2019
1
DOP64: Minimal additional benefits in adding fecal hemoglobin to fecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel diseaseECCO'19 Copenhagen
2019
1
DOP65: The association of fecal calprotectin level and combined mucosal and transmural healing in patients with Crohn's diseaseECCO'19 Copenhagen
2019
1
DOP66: Surveillance colonoscopies in Ulcerative Colitis: Does it make a difference?ECCO'19 Copenhagen
2019
1
DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histologic inflammation in patients with inflammatory bowel diseaseECCO'19 Copenhagen
2019
1
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's diseaseECCO'19 Copenhagen
2019
1
DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in ulcerative colitisECCO'19 Copenhagen
2019
1
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasiaECCO'19 Copenhagen
2019
1
DOP73: Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trialECCO'19 Copenhagen
2019
1
DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multicenter observational study.ECCO'19 Copenhagen
2019
1
DOP76: Prevalence and health-care costs of perianal fistulas in Crohn’s disease in a nationwide cohortECCO'19 Copenhagen
2019
1
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multicenter observational studyECCO'19 Copenhagen
2019
1
DOP79: Effect of vedolizumab on surgical rates in IBD: Post hoc analysis from the GEMINI trialsECCO'19 Copenhagen
2019
1
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial.ECCO'19 Copenhagen
2019
1
DOP81: Utility of a Simple Blood Test for Mucosal Healing Monitoring is Accurate in Post-Operative Crohn’s DiseaseECCO'19 Copenhagen
2019
1
DOP82: Direct and indirect costs of inflammatory bowel disease in the biological era; ten years of follow up in a Danish population-based inception cohortECCO'19 Copenhagen
2019
1
DOP85: Rising depression and antidepressant use amongst Inflammatory Bowel Disease patientsECCO'19 Copenhagen
2019
1